June 21, 2021

The Honorable Patrick Leahy
Chairman
Senate Committee on Appropriations
The Capitol, Room S-128
Washington, DC 20510

The Honorable Richard Shelby
Vice Chairman
Senate Committee on Appropriations
The Capitol, Room S-146A
Washington, DC 20510

The Honorable Patty Murray
Chair
Subcommittee on Labor, Health and Human Services, and Education, and Related Agencies
Dirksen Senate Office Building, Room 136
Washington, DC 20510

The Honorable Roy Blunt
Ranking Member
Subcommittee on Labor, Health and Human Services, and Related Agencies
Dirksen Senate Office Building, Room 156
Washington, DC 20510

Dear Chairman Leahy, Vice Chairman Shelby, Chair Murray, and Ranking Member Blunt:

As you and your colleagues begin to work on the Fiscal Year (FY) 2022 appropriations bills, we respectfully request that you maintain a strong commitment to funding for the National Institutes of Health (NIH) in the Labor-Health and Human Services-Education bill. For the past five years, NIH has been able to advance biomedical innovation and research because of sustained investments. Following a year like no other in our Nation’s recent history, we have seen unprecedented advances in biomedical science in response to the COVID-19 pandemic, advances that would not have been possible without the groundwork laid over many years of investment in basic research. We commend the Appropriators for continuing to recognize the critical role support for the NIH plays in spurring continued discoveries that will save and improve lives, and lay the foundation for new treatments and therapies that may help the United States address our most challenging public health needs. As researchers around the country confront the impact of the pandemic, including on their work, now, more than ever, it is essential to continue this federal support for the benefit of the American people and the importance of ensuring that our Nation remains at the forefront of medical research.

The NIH is our country’s premier institution for biomedical innovation, supporting research in all fifty states. It offers our best hope for treating or curing debilitating diseases, such as heart disease, cancer, diabetes and so many other illnesses that American families battle every day. It is through NIH-supported innovative medical research that we will learn more about emerging conditions resulting from the pandemic, and conduct early stage research to rapidly identify solutions to this and future public health challenges. Demographic changes and the escalating expenses associated with chronic medical conditions cost the federal government and private sector hundreds of billions of dollars each year, but NIH research has laid the groundwork to help curb those trends.
Our investment in the NIH has supported biomedical research in times of triumph, such as when NIH-led researchers decoded the human genome, and in times of trial, such as the current COVID-19 pandemic. The results of this research contribute to improved health outcomes and economic growth. NIH grants fund basic, clinical and translational research that turns bench-side findings into bedside interventions for patients. NIH supports the work of over 300,000 individuals focused on cutting-edge biomedical research at 2,500 institutions across the country. Unfortunately, America has struggled to maintain its position as the world leader in research and development, and researchers have similarly struggled to secure funding. As NIH grants become more competitive, researchers can easily spend half their careers working before receiving a grant. Secure NIH funding allows scientists to do what they do best—discover tomorrow’s therapies and cures. It also prevents promising, talented young researchers from leaving the field of biomedical research and ensures that seasoned investigators continue to conduct their research in the United States. We hope that a sustained commitment to NIH funding will help reverse these troubling trends.

We all recognize the difficult choices that need to be made with respect to the budget as we seek to address the ongoing economic crisis caused by the COVID-19 pandemic. If we are to continue grappling with emerging threats, as well as improve the health of Americans and the quality of their lives, we must continue to invest in biomedical research that has the potential to save money, improve lives and offer an economic return for our Nation. As your Committee makes funding decisions for FY 2022, we urge you to consider the tremendous benefits of sustained investment in the NIH and ask you to remember our Nation’s role as a world leader in biomedical research and the impact this research has on the American people. We also ask that you include the full allocation of funding for the NIH provided by the 21st Century Cures Act. Investing in research today will continue to yield cures and therapies for patients tomorrow.

Sincerely,

Robert P. Casey, Jr.
United States Senator

Richard Burr
United States Senator

Edward J. Markey
United States Senator

Angus S. King, Jr.
United States Senator
James E. Risch
United States Senator

Cory A. Booker
United States Senator

Jacky Rosen
United States Senator

Brian Schatz
United States Senator

Rick Scott
United States Senator

Sherrod Brown
United States Senator

Elizabeth Warren
United States Senator

Richard J. Durbin
United States Senator

Debbie Stabenow
United States Senator

Sheldon Whitehouse
United States Senator